Pyrimidine PDE10 Inhibitors for Schizophrenia Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antipsychotic treatments for schizophrenia are inadequate due to low efficacy and severe side effects, leading to high medication noncompliance, and there is a need for therapeutic agents that can effectively target phosphodiesterase 10 (PDE10) to modulate cyclic nucleotide levels in the brain.
Innovation Solution
Development of pyrimidine compounds that act as selective inhibitors of PDE10, specifically designed to increase cAMP and/or cGMP levels in neurons, which are useful for treating schizophrenia and other neurological disorders by modulating striatal function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current antipsychotic treatments (typical or atypical) are used, then some therapeutic effect is achieved, but severe side effects occur including metabolic, extrapyramidal, prolactic and cardiac adverse events
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular structures (pyrimidine cores with particular substituent patterns) that selectively target PDE10A enzyme in the striatum while avoiding off-target effects on other PDE isoforms and receptors. This structural specificity enables the drug to exert therapeutic effects locally in the dopaminergic pathway without triggering systemic side effects associated with conventional antipsychotics that broadly affect multiple neurotransmitter systems
Solution Approach 2:
The patent employs parameter changes by optimizing key molecular parameters including the pyrimidine ring substitution patterns, linker chain lengths, and heterocyclic group compositions to achieve optimal PDE10A binding affinity and selectivity. By systematically varying these chemical parameters, the invention achieves enhanced therapeutic efficacy with reduced side effect profile compared to conventional antipsychotics
2Reliability
If current antipsychotic treatments are used, then some symptom relief is provided, but medication noncompliance rate is extremely high due to intolerable side effects
Solution Approach 1:
The patent converts the harmful side effect profile of conventional antipsychotics into a benefit by specifically targeting PDE10A, which is highly expressed in the striatum and involved in dopaminergic signaling. By focusing therapeutic action on this specific enzyme rather than broadly blocking dopamine receptors, the invention achieves symptom relief while avoiding the intolerable side effects that cause noncompliance, thereby transforming the treatment approach from harmful to beneficial
3Reliability
If selective PDE10 inhibitors are developed, then therapeutic benefits for schizophrenia and neurological disorders can be achieved, but the complexity of identifying selective inhibitors across multiple PDE families increases
Solution Approach 1:
The patent applies segmentation by dividing the PDE superfamily into distinct functional groups and focusing specifically on PDE10A, which has unique characteristics including high striatal expression and involvement in dopaminergic pathways. By segmenting the target selection process and concentrating on this specific isoform rather than attempting to inhibit all PDEs, the invention simplifies the development complexity while achieving therapeutic benefits for schizophrenia and neurological disorders
Data Source
AI summary
The present invention is directed to pyrimidine compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.